Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer

Young Seok Seo, Mi Sook Kim, Sung Yul Yoo, Chul Koo Cho, Kwang Mo Yang, Hyung Jun Yoo, Chul Won Choi, Dong Han Lee, Jin Kim, Min Suk Kim, Hye Jin Kang, Young Han Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0% and 70.2%, respectively. One patient (3%) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)1456-1461
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume75
Issue number5
DOIs
Publication statusPublished - 2009 Dec 1
Externally publishedYes

Fingerprint

acceleration (physics)
Pancreatic Neoplasms
radiation therapy
Radiotherapy
cancer
progressions
toxicity
Disease-Free Survival
dosage
Survival
carbohydrates
antigens
chemotherapy
grade
Survival Rate
Carbohydrates
Radiation
Antigens
Drug Therapy
radiation

Keywords

  • CyberKnife
  • Pancreatic cancer
  • Radiation therapy
  • Stereotactic

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer. / Seo, Young Seok; Kim, Mi Sook; Yoo, Sung Yul; Cho, Chul Koo; Yang, Kwang Mo; Yoo, Hyung Jun; Choi, Chul Won; Lee, Dong Han; Kim, Jin; Kim, Min Suk; Kang, Hye Jin; Kim, Young Han.

In: International Journal of Radiation Oncology Biology Physics, Vol. 75, No. 5, 01.12.2009, p. 1456-1461.

Research output: Contribution to journalArticle

Seo, YS, Kim, MS, Yoo, SY, Cho, CK, Yang, KM, Yoo, HJ, Choi, CW, Lee, DH, Kim, J, Kim, MS, Kang, HJ & Kim, YH 2009, 'Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer', International Journal of Radiation Oncology Biology Physics, vol. 75, no. 5, pp. 1456-1461. https://doi.org/10.1016/j.ijrobp.2009.01.042
Seo, Young Seok ; Kim, Mi Sook ; Yoo, Sung Yul ; Cho, Chul Koo ; Yang, Kwang Mo ; Yoo, Hyung Jun ; Choi, Chul Won ; Lee, Dong Han ; Kim, Jin ; Kim, Min Suk ; Kang, Hye Jin ; Kim, Young Han. / Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 75, No. 5. pp. 1456-1461.
@article{65ed2aae56e649d793a62cd5111cdadd,
title = "Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer",
abstract = "Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0{\%} and 70.2{\%}, respectively. One patient (3{\%}) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.",
keywords = "CyberKnife, Pancreatic cancer, Radiation therapy, Stereotactic",
author = "Seo, {Young Seok} and Kim, {Mi Sook} and Yoo, {Sung Yul} and Cho, {Chul Koo} and Yang, {Kwang Mo} and Yoo, {Hyung Jun} and Choi, {Chul Won} and Lee, {Dong Han} and Jin Kim and Kim, {Min Suk} and Kang, {Hye Jin} and Kim, {Young Han}",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.ijrobp.2009.01.042",
language = "English",
volume = "75",
pages = "1456--1461",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer

AU - Seo, Young Seok

AU - Kim, Mi Sook

AU - Yoo, Sung Yul

AU - Cho, Chul Koo

AU - Yang, Kwang Mo

AU - Yoo, Hyung Jun

AU - Choi, Chul Won

AU - Lee, Dong Han

AU - Kim, Jin

AU - Kim, Min Suk

AU - Kang, Hye Jin

AU - Kim, Young Han

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0% and 70.2%, respectively. One patient (3%) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.

AB - Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0% and 70.2%, respectively. One patient (3%) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.

KW - CyberKnife

KW - Pancreatic cancer

KW - Radiation therapy

KW - Stereotactic

UR - http://www.scopus.com/inward/record.url?scp=71649106367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649106367&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.01.042

DO - 10.1016/j.ijrobp.2009.01.042

M3 - Article

C2 - 19783379

AN - SCOPUS:71649106367

VL - 75

SP - 1456

EP - 1461

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -